文献速递免疫规划传染病防控与疫情报告

SARS-CoV-2合成DNA疫苗INO-4800单剂或两剂方案在非人灵长类攻毒模型中保护呼吸道疾病负担

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
PubMed 文献 · Vaccine · 2021-06-23

在恒河猴模型中评估皮内接种编码SARS-CoV-2刺突蛋白的合成DNA疫苗INO-4800的安全性和免疫原性及 efficacy,单剂和两剂方案均诱导结合抗体和中和抗体以及IFN-γ-producing T细胞,高病毒剂量攻毒后接种动物肺和喉病毒载量显著降低,两剂方案免疫应答更稳健且病毒保护更好,肺组织病理学检查未提示疫苗增强疾病。

要点

  • INO-4800单剂或两剂皮内接种均诱导结合抗体、中和抗体及IFN-γ T细胞
  • 高剂量攻毒后接种组肺和喉病毒载量较对照组显著降低
  • 两剂方案免疫应答更稳健且病毒保护更优,肺病理未提示疫苗增强疾病

核心结论

  • INO-4800单剂或两剂皮内接种在恒河猴中诱导体液和细胞免疫,高剂量攻毒后显著降低肺和喉病毒载量,两剂方案免疫应答和保护更优,未提示疫苗增强疾病。

研究设计与样本

  • 在恒河猴模型中评估皮内接种合成DNA疫苗INO-4800的安全性和免疫原性及 efficacy,比较单剂和两剂接种方案。

主要发现

  • 接种诱导针对SARS-CoV-2的结合抗体和中和抗体以及IFN-γ-producing T细胞。
  • 经鼻内和气管内途径给予高病毒剂量(5 × 10^6 pfu)后,接种动物肺和喉病毒载量较对照组显著降低。
  • 两剂INO-4800与更稳健的疫苗诱导免疫应答和 improved viral protection 相关。
  • 肺组织病理学检查未提示INO-4800免疫动物在SARS-CoV-2攻毒后出现疫苗增强疾病。

临床怎么用

  • 该候选疫苗目前正以两剂方案进行临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed the safety, immunogenicity and efficacy of the intradermal delivery of INO-4800, a synthetic DNA vaccine candidate encoding the SARS-CoV-2 spike protein in the rhesus macaque model. Single and 2 dose vaccination regimens were evaluated. Vaccination induced both binding and neutralizing antibodies, along with IFN-γ-producing T cells against SARS-CoV-2. Upon administration of a high viral dose (5 × 106 pfu) via the intranasal and intratracheal routes we observed significantly reduced virus load in the lung and throat, in the vaccinated animals compared to controls. 2 doses of INO-4800 was associated with more robust vaccine-induced immune responses and improved viral protection. Importantly, histopathological examination of lung tissue provided no indication of vaccine-enhanced disease following SARS-CoV-2 challenge in INO-4800 immunized animals. This vaccine candidate is currently under clinical evaluation as a 2 dose regimen.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gooch KE, Smith TRF, Salguero FJ, et al. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. Vaccine. 2021. PMID: 34253420. doi:10.1016/j.vaccine.2021.06.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。